cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Io Biotech Inc
2 own
2 watching
Current Price
$2.7
$-0.02
(-0.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
77.8M
52-Week High
52-Week High
9.77
52-Week Low
52-Week Low
2.15
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization77.8M
icon52-Week High9.77
icon52-Week Low2.15
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Io Biotech Inc do?
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company s lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More
How much money does Io Biotech Inc make?
News & Events about Io Biotech Inc.
Globe Newswire
12days ago
Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-...
Globe Newswire
26days ago
Independent data monitoring committee recommends that the companys Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling patients at more than 80 active sites globally. Encouraging ...
Benzinga
2 months ago
Latest Ratings for IOBT DateFirmActionFromTo Nov 2021Morgan StanleyInitiates Coverage OnOverweight Nov 2021Cowen & Co.Initiates Coverage OnOutperform Nov 2021JefferiesInitiates Coverage OnBuy View More Analyst Ratings for IOBT View the Latest Analyst Ratings read more...
Globe Newswire
3 months ago
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced today that Mai-Britt Zocca, Ph.D., the companys President and CEO, and Amy Sullivan...
Globe Newswire
4 months ago
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced an oral presentation and two poster presentations at the Society for Immunotherapy ...
Frequently Asked Questions
Frequently Asked Questions
What is Io Biotech Inc share price today?
plus_minus_icon
Can Indians buy Io Biotech Inc shares?
plus_minus_icon
How can I buy Io Biotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Io Biotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Io Biotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Io Biotech Inc?
plus_minus_icon
What is today’s market capitalisation of Io Biotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Io Biotech Inc?
plus_minus_icon
What percentage is Io Biotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Io Biotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.7
$-0.02
(-0.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00